Dr. Gerber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Rd Seay Biomedical Building 2nd floor
Dallas, TX 75390Phone+1 214-645-4673
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2000 - 2004
Weill Cornell MedicineClass of 2000
Certifications & Licensure
TX State Medical License 2002 - 2026
MD State Medical License 2004 - 2008- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2005 Jun 01
- Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
- Clinical Trial of ARQ 761 in Advanced Solid Tumors Start of enrollment: 2011 Dec 29
- Join now to see all
Publications & Presentations
PubMed
- Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.Mitchell S von Itzstein, Jialiang Liu, Hong Mu-Mosley, Farjana Fattah, Jason Y Park
JTO Clinical and Research Reports. 2025-01-01 - Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brie...Yuanyuan Zhang, Puneeth Iyengar, Steven Montalvo, Kenneth D Westover, Sawsan Rashdan
International Journal of Radiation Oncology, Biology, Physics. 2025-01-01 - Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer.Mitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, Leora Horn, D Ross Camidge
Clinical Cancer Research. 2024-12-09
Journal Articles
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesDavid E Gerber, Jonathan E Dowell, Clinical Lung Cancer
Lectures
- Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical TrialsClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Underlying host immune dysregulation in cancer patients developing immune-related adverse events.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Authored Content
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published CasesNovember 2018
Press Mentions
Weight-Based Immunotherapy Dosing May Benefit Patients with Cancer and High BMIJune 22nd, 2021
UT Southwestern: Criteria for Clinical Trials Might Be Too StrictDecember 10th, 2019
Strange Signs: Cancer-Related Paraneoplastic SyndromesNovember 15th, 2019- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
